Cancer immunotherapy has made tremendous clinical progress in advanced-stage
malignancies. However, patients with various tumors exhibit a low response rate to …

Bioactive materials are a kind of materials with unique bioactivities, which can change the
cellular behaviors and elicit biological responses from living tissues. Bioactive materials …

Cancer nanomedicines were initially envisioned as magic bullets, travelling through the
circulation to target tumours while sparing healthy tissues the toxicity of classic …

The tumor development and metastasis are closely related to the structure and function of
the tumor microenvironment (TME). Recently, TME modulation strategies have attracted …

Recent years have witnessed increasingly rapid advances in nanocarrier-based
biomedicine aimed at improving treatment paradigms for cancer. Nanogels serve as …

The successful clinical application of immune checkpoint blockade (ICB) and chimeric
antigen receptor T cells (CAR-T) therapeutics has attracted extensive attention to …

Current cancer immunotherapy [eg, immune checkpoint blockade (ICB)] only benefits small
subsets of patients, largely due to immunosuppressive tumor microenvironment (TME). In …

A major challenge in cancer vaccine therapy is the efficient delivery of antigens and
adjuvants to stimulate a controlled yet robust tumour-specific T-cell response. Here, we …

Therapeutic targeting of the immune system in cancer is now a clinical reality and marked
successes have been achieved, most notably through the use of checkpoint blockade …

Nanomedicines are extensively employed in cancer therapy. We here propose four strategic
directions to improve nanomedicine translation and exploitation.(1) Patient stratification has …